The proteasome inhibitor bortezomib, a plasma cell-depleting agent, has been used to treat multiple myeloma by inhibiting the transcriptional factor nuclear facto-kappa B (NF-κB) and inducing the apoptosis of myeloma cells through a misfolded protein response. Here, NFKB1 is linked to plasma cell myeloma.